Next Article in Journal
Role of Angiopoietin-2 in Vascular Physiology and Pathophysiology
Next Article in Special Issue
An In Vitro System for Evaluating Molecular Targeted Drugs Using Lung Patient-Derived Tumor Organoids
Previous Article in Journal
Modelling of Neuronal Ceroid Lipofuscinosis Type 2 in Dictyostelium discoideum Suggests That Cytopathological Outcomes Result from Altered TOR Signalling
Previous Article in Special Issue
Patient Derived Chicken Egg Tumor Model (PDcE Model): Current Status and Critical Issues
Article Menu

Export Article

Open AccessReview

Application of Cancer Organoid Model for Drug Screening and Personalized Therapy

Department of Clinical Bio-resource Research and Development, Graduate School of Medicine Kyoto University, Kyoto 606-8501, Japan
*
Author to whom correspondence should be addressed.
Cells 2019, 8(5), 470; https://doi.org/10.3390/cells8050470
Received: 30 April 2019 / Revised: 13 May 2019 / Accepted: 14 May 2019 / Published: 17 May 2019
  |  
PDF [693 KB, uploaded 17 May 2019]
  |     |  

Abstract

Drug screening—i.e., testing the effects of a number of drugs in multiple cell lines—is used for drug discovery and development, and can also be performed to evaluate the heterogeneity of a disease entity. Notably, intertumoral heterogeneity is a large hurdle to overcome for establishing standard cancer treatment, necessitating disease models better than conventional established 2D cell lines for screening novel treatment candidates. In the present review, we outline recent progress regarding experimental cancer models having more physiological and clinical relevance for drug screening, which are important for the successful evaluation of cellular response to drugs. The review is particularly focused on drug screening using the cancer organoid model, which is emerging as a better physiological disease model than conventional established 2D cell lines. We also review the use of cancer organoids to examine intertumor and intratumor heterogeneity, and introduce the perspective of the clinical use of cancer organoids to enable precision medicine. View Full-Text
Keywords: drug screening; cancer; cell lines; organoid; spheroid; heterogeneity; precision medicine drug screening; cancer; cell lines; organoid; spheroid; heterogeneity; precision medicine
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Kondo, J.; Inoue, M. Application of Cancer Organoid Model for Drug Screening and Personalized Therapy. Cells 2019, 8, 470.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cells EISSN 2073-4409 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top